Market Research Logo

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2016

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2016’, provides an overview of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
    • The report reviews pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics and enlists all their major and minor projects
    • The report assesses Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Overview
    Therapeutics Development
    Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Overview
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics under Development by Companies
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Products under Development by Companies
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Companies Involved in Therapeutics Development
    3SBio Inc.
    AkaRx Inc
    Amgen Inc.
    arGEN-X BV
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb Company
    Genosco
    Hansa Medical AB
    Immunomedics, Inc.
    Intas Pharmaceuticals Ltd.
    Jiangsu Hengrui Medicine Co., Ltd.
    Merck & Co., Inc.
    Momenta Pharmaceuticals, Inc.
    Novartis AG
    Pfizer Inc.
    PhytoHealth Corporation
    Protalex, Inc.
    Rigel Pharmaceuticals, Inc.
    Shire Plc
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    Antibody for Autoimmune Disorders and Inflammation - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ARGX-113 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    avatrombopag - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BI-655064 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BMS-986004 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    eltrombopag olamine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    eltrombopag olamine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    fostamatinib disodium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GL-2045 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GSK-2285921 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Hetrombopag Olamine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    M-281 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MK-8723 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PHN-013 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PRTX-100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    romiplostim - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    romiplostim biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SKIO-703 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SM-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    thrombopoietin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    veltuzumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Product Development Milestones
    Featured News & Press Releases
    Jun 10, 2016: Novartis highlights long-term safety data of Revolade in adults with chronic immune thrombocytopenia, a rare blood disorder
    May 19, 2016: Amgen Highlights Data on Nplate (romiplostim) at 21st Congress Of The European Hematology Association
    Apr 07, 2016: Novartis receives EU approval for Revolade as first-in-class therapy for children aged 1 year and above with chronic ITP
    Apr 01, 2016: Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP
    Jan 29, 2016: CHMP adopts extension to existing therapeutic indication for eltrombopag
    Jan 28, 2016: Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP
    Jan 07, 2016: Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco
    Sep 08, 2015: Rigel Granted Orphan Drug Designation for Fostamatinib in ITP
    Jun 11, 2015: Novartis gains FDA approval for Promacta providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder
    Feb 06, 2015: GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade)
    Dec 22, 2014: GSK announces US regulatory submission seeking additional indication for eltrombopag (Promacta)
    Jul 16, 2014: Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
    Oct 31, 2013: Kyowa Hakko Kirin Announces Launch Of Nplate In Taiwan
    Oct 24, 2013: Rigel Provides Update On Oral SYK Inhibitor Fostamatinib
    Jul 24, 2013: NICE says yes to blood disorder treatment in final guidance
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016 (Contd..1)
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by 3SBio Inc., H2 2016
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by AkaRx Inc, H2 2016
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Amgen Inc., H2 2016
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by arGEN-X BV, H2 2016
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Boehringer Ingelheim GmbH, H2 2016
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Bristol-Myers Squibb Company, H2 2016
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Genosco, H2 2016
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Hansa Medical AB, H2 2016
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Immunomedics, Inc., H2 2016
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Intas Pharmaceuticals Ltd., H2 2016
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Merck & Co., Inc., H2 2016
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Novartis AG, H2 2016
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pfizer Inc., H2 2016
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by PhytoHealth Corporation, H2 2016
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Protalex, Inc., H2 2016
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Shire Plc, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects, H2 2016
    Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Targets, H2 2016
    Number of Products by Stage and Targets, H2 2016
    Number of Products by Mechanism of Actions, H2 2016
    Number of Products by Stage and Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report